Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(dihydroxyboranyl)-2-({[4-(phenylsulfonyl)thiophen-2-yl]sulfonyl}amino)benzoic acid
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the sulfanilide class, characterized by a benzoic acid core substituted with dihydroxyboranyl and sulfonamide groups. It was designed as an experimental inhibitor of AmpC beta-lactamase, an enzyme produced by certain bacteria (notably Escherichia coli), which confers resistance to beta-lactam antibiotics. Structural studies have shown that this boronic acid derivative binds covalently to the active site serine of AmpC beta-lactamase, acting as a potent inhibitor and serving as a lead compound for further development of antibiotic resistance modulators. The molecule has been studied primarily in vitro and in structural biology contexts; it is not approved for clinical use[1][5][8].
- Other names
- 2-[4-(benzenesulfonyl)thiophene-2-sulfonamido]-4-(dihydroxyboranyl)benzoic acid4-(Dihydroxyboryl)-2-({[4-(phenylsulfonyl)-2-thienyl]sulfonyl}amino)benzoic acid
02
Targets
AmpC (AmpC beta-lactamase)
Beyond the preview
Go deeper on 4-(dihydroxyboranyl)-2-({[4-(phenylsulfonyl)thiophen-2-yl]sulfonyl}amino)benzoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-(dihydroxyboranyl)-2-({[4-(phenylsulfonyl)thiophen-2-yl]sulfonyl}amino)benzoic acid.